Calfactant

Drug Profile

Calfactant

Alternative Names: Infasurf

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Ony
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neonatal respiratory distress syndrome
  • No development reported Acute lung injury
  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 28 Feb 2017 Ony plans a phase III trial for Respiratory distress syndrome (In neonates) (NCT03058666)
  • 16 Apr 2015 Ikaria Holdings has been acquired by Mallinckrodt plc
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top